As many as 10 million people in the United States have photoreceptor degenerative diseases

Necessary .Cell Technology Files IND FDA for First Clinical Study with Human Embryonic Stem Cells Treat Eye DiseaseAdvanced Cell Technology announced that it has an Investigational New Drug application filed with the U.S. Food and Drug Administration to treat to initiate a phase I / II multicenter study using embryonic stem cell -derived retinal cells in patients with Stargardt’s Macular Dystrophy . The most common causes of untreatable blindness in the world are degenerative diseases of the retina. As many as 10 million people in the United States have photoreceptor degenerative diseases. While most of these patients have age-related macular degeneration , a smaller number of patients have Stargardt disease, a rare disease and one of the most common forms of juvenile macular degeneration blindness. The treatment for diseases of the eye using a kind of cell stem create a new one in the retina , which supports photoreceptors for vision necessary. These cells known as retinal pigment epithelium , are often the to die off to die off in SMD and AMD macular loss of vision. Source Advanced Cell Technology.

Describe Schepens senior scientist, Patricia A. D’Amore, on what to do about the causes of these devastating condition and some of the most work at the Institute to find cure is known. D’Amore, well as also on the HMS has much on of her career devoted on the examining the relationship among growth of blood vessels and eye conditions and is the basic research, new medications as Lucentis which are active, led helped slow the progression the macular degeneration.

The latest research on macular degeneration and its causes, possible cures, Currently treatment and strategy for living well with it will be the focus of the first Cape Cod related Macular Degeneration Conference on his 17th September. Free public training Programme, the symposium will be held last of 9 till noon on the Barnstable Senior Centre, 825 Falmouth Road Hyannis.